MAPK3 and colorectal carcinoma: Third, although the ERK1/2 inhibitor completely abolished GXYLT1S212*-induced metastasis and the mutation site may serve as a therapy indicator, further studies are required to justify the potential of ERK1/2 inhibitors to treat GXYLT1-mutant CRC.